Since obesity is a major risk factor for endometrial cancer, we explored a dual treatment strategy by combining a weight loss drug (semaglutide—a glucagon-like peptide-1 (GLP-1) agonist) with a progestin. This evidence concerns the gene GLP1R and endometrial cancer.